Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:31:14 EDT Sat 05 Sep 2026
Enter Symbol
or Name
USA
CA



Q:NEO - NEOGENOMICS INC - https://www.neogenomics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NEO - Q0.217.21·19.400.117.38-0.08-0.5997.016,51813,54917.20  17.47  16.86519.76  7.06519:53:13Sep 0115 min RT 2¢

Recent Trades - Last 10 of 13549
Time ETExPriceChangeVolume
19:53:13Q17.500.042
19:30:02Q17.88870.42871
19:30:02Q17.88870.42871
19:30:01Q17.88870.42871
19:28:05Q17.630.171
19:11:35Q17.88870.4287150
17:59:19Q17.630.1726
17:59:19Q17.630.172
17:59:19Q17.96990.50993
16:50:51Q17.1916-0.2684211

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-01 07:05U:NEONews ReleaseNeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-26 16:17U:NEONews ReleaseNeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
2026-07-28 16:05U:NEONews ReleaseNeoGenomics Reports Second Quarter 2026 Results
2026-07-20 17:23U:NEONews ReleaseNeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
2026-07-09 07:05U:NEONews ReleaseNeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
2026-07-07 07:05U:NEONews ReleaseNeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
2026-06-25 07:05U:NEONews ReleaseNeoGenomics Appoints Carolyn Starrett to its Board of Directors
2026-06-17 06:00U:NEONews ReleaseNeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
2026-06-15 17:24U:NEONews ReleaseNeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
2026-05-26 07:05U:NEONews ReleaseNeoGenomics to Present New Research at ASCO Annual Meeting 2026
2026-05-15 09:05U:NEONews ReleaseNeoGenomics to Participate in Upcoming Investor Conferences
2026-04-28 16:05U:NEONews ReleaseNeoGenomics Reports First Quarter 2026 Results
2026-04-23 07:05U:NEONews ReleaseNeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
2026-04-13 07:05U:NEONews ReleaseNeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
2026-04-07 07:05U:NEONews ReleaseNeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
2026-03-16 07:05U:NEONews ReleaseNeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
2026-02-25 07:05U:NEONews ReleaseNeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
2026-02-18 07:05U:NEONews ReleaseNeoGenomics to Participate in Upcoming Investor Conferences
2026-02-17 07:05U:NEONews ReleaseNeoGenomics Reports Fourth Quarter and Full Year 2025 Results
2026-02-12 07:05U:NEONews ReleaseNeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection